Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer

NCT04506554 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT04506554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04506554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 1, 2020
Completion date
November 30, 2028
Enrollment
81 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

muscle-invasive bladder carcinoma